Skip to main content

Researcher excited after HIV cases go into remission following stem cell use

HIV-positive is a chronic condition that can be controlled with daily doses of medicines but there’s no known cure. However, there have now been three cases of HIV being put into remission that a D.C.-area researcher finds “exciting.”

The research was conducted by the International Maternal Pediatric Adolescent AIDS Clinical Trial Network that is funded by the National Institutes of Health.

Each case, the most recent announced on Feb. 15, involved use of stem cells modified to prevent the ability of HIV to replicate and continue to infect the body.

The use of those stem cells, however, happened under extreme circumstances.



“All had acute leukemia; all had to go through severe chemotherapy; and then had a stem cell transplant. Those are not simple, benign treatments that everyone could have,” said Dr. Michael Horberg, an infectious disease doctor at Kaiser Permanente, who is a leading HIV/AIDS researcher. Horberg was not affiliated with the published findings.

Dr. Michael Horberg, an infectious disease doctor at Kaiser Permanente who is a leading HIV/AIDS researcher. (Courtesy Kaiser Permanente/Elliott O’Donovan)

The third case of remission has the study’s team saying that “stem cell transplantation should be considered to achieve HIV remission and cure for people living with HIV who require such a transplant for other diseases.”

The first case of remission involved a man who lived 12 years in remission and was considered cured before dying of leukemia in September 2020. The second case involves a man who has been in HIV remission for more than 30 months. The third case involves a woman who has had no detectable HIV in the 14 months since she stopped taking antiretroviral therapy.

“It’s very exciting. I have been practicing HIV medicine since 1988. So for me to see the evolution of treatment, evolution of patients living longer has always been a great encouragement,” Horberg said. “Of course, the goal has always been to find a cure. And this is just one more bit of knowledge on that path to finding a cure.”

States seek to lower drug prices by targeting the companies that manage them for health plans

TOPEKA, Kan. (AP) — As consumers worry about medication costs, states are trying to lower drug prices by reining in big companies that oversee prescription coverage for health insurers. Some of those companies, called pharmacy benefit managers, also own pharmacies, and one of them, CVS, has spent millions of dollars fighting the regulations. Affordability is a key issue ahead of this year’s midterm elections. Legislators in at least a dozen states passed laws this year to limit compensation to the companies, set minimum payments from the companies to pharmacists and require the companies to disclose more information to their clients, states and the public. A Tennessee law will bar pharmacy benefit managers from operating retail pharmacies as of July 1, 2028, though CVS Health Corp. has filed a federal lawsuit to avoid having to close its 136 pharmacies there.
Read Next Story